Document is current
Any future updates will be listed below
-
Authors
Bowen, Ellen R. https://orcid.org/0000-0001-8089-0944
DiGiacomo, Phillip
Fraser, Hannah P. https://orcid.org/0000-0002-3733-5459
Guttenplan, Kevin https://orcid.org/0000-0003-4242-4349
Smith, Benjamin A. H. https://orcid.org/0000-0001-8802-416X
Heberling, Marlene L. https://orcid.org/0000-0002-2316-9349
Vidano, Laura https://orcid.org/0000-0002-9473-7913
Shah, Nigam https://orcid.org/0000-0001-9385-7158
Shamloo, Mehrdad
Wilson, Jennifer L. https://orcid.org/0000-0002-2328-2018
Grimes, Kevin V. https://orcid.org/0000-0003-2469-2366
-
Funding
Funding for this research was provided by:
Spark at Stanford
National Institutes of Health (T32GM113854, 1R01AG054533-01A1, 1R01AG054533-01A1)
Sanofi iDEA
- License Information
-
More Information
Article History
Received: 19 October 2023
Accepted: 26 October 2023
First Online: 30 November 2023
Declarations
:
: Mehrdad Shamloo is a co-founder of CuraSen Therapeutics, a company developing adrenergic drugs for the treatment of neurodegenerative disease. He owns shares of stock in CuraSen Therapeutics. All other authors declare no conflict of interest.
